Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Autolus Therapeutics' EBITDA Margin history spans 6 years, with the latest figure at 373.7% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 19232285.0% year-over-year to 373.7%; the TTM value through Dec 2025 reached 349.8%, up 183051.0%, while the annual FY2025 figure was 349.8%, 183245.0% up from the prior year.
  • EBITDA Margin reached 373.7% in Q4 2025 per AUTL's latest filing, up from 400.59% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 138.36% in Q2 2025 to a low of 192696.55% in Q4 2024.
  • Average EBITDA Margin over 4 years is 26331.22%, with a median of 657.9% recorded in 2025.
  • The largest YoY upside for EBITDA Margin was 19232285bps in 2025 against a maximum downside of -13680bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 26817.47% in 2022, then skyrocketed by 53bps to 12730.54% in 2023, then tumbled by -1414bps to 192696.55% in 2024, then skyrocketed by 100bps to 373.7% in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EBITDA Margin are 373.7% (Q4 2025), 400.59% (Q3 2025), and 138.36% (Q2 2025).